September 2016
Volume 57, Issue 12
Open Access
ARVO Annual Meeting Abstract  |   September 2016
Author Affiliations & Notes
  • Luigi Zompatori
    Tivoli Hospital, Tivoli, Italy
  • Elisabetta Sterbini
    Tivoli Hospital, Tivoli, Italy
  • Roberta Salvati
    Tivoli Hospital, Tivoli, Italy
  • Simona Altimari
    Tivoli Hospital, Tivoli, Italy
  • Footnotes
    Commercial Relationships   Luigi Zompatori, None; Elisabetta Sterbini, None; Roberta Salvati, None; Simona Altimari, None
  • Footnotes
    Support  None
Investigative Ophthalmology & Visual Science September 2016, Vol.57, 3261. doi:
  • Views
  • Share
  • Tools
    • Alerts
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Luigi Zompatori, Elisabetta Sterbini, Roberta Salvati, Simona Altimari; VARIATIONS OF THE DIABETIC MACULAR EDEMA AFTER CATARACT SURGERY ON PATIENTS BEING TREATED WITH NSAIDs AND/OR RESVERATROL SUPPLEMENTS.. Invest. Ophthalmol. Vis. Sci. 2016;57(12):3261.

      Download citation file:

      © ARVO (1962-2015); The Authors (2016-present)

  • Supplements

Purpose : To evaluate, with OCT, macular modifications in diabetic patients who have undergone phacoemulsification cataract surgery and are being treated with topical NSAIDs and/or Resveratrol supplements in order to evaluate the possibility that these drugs have a protective effect on patients.

Methods : We evaluated both visus and macular retina thickness using OCT Spectral Domain at T0 (the moment in which the patients signed up for the experiment), at T1 (one week after surgery), at T2 (one month after surgery) and at T3 (two months after surgery) in four groups of 15 patients, each affected by type II diabetes. The patients were administered (along with the usual post-surgery medications): group 1 - classical therapy with topical corticosteroids; group 2 - topical NSAIDs (Brofenac eyedrops: 1 drop 3 times per day); group 3 - Resveratrol supplements (1 tablet/day); while to patients in group 4 both drugs were administered.

Results : Two months after surgery all three groups showed a significant increase of the visus, but only group 4 showed a higher average visus after just one week. As for OCT thickness, the group 1 presented to one week a significant increase (T0 242,27 μ- T1 283,87 μ; p< 0.02) of the oedema, wich continues to increase in a non significant ( T1 283,87μ - T3 297,93μ; p>0.02) manner to two months (T0 242,27μ - T3 297,93μ; p<0.02). The group treated with only NSAIDs presented an inferior worsening of the oedema after a week, which, although showing improvement later, never returned to starting conditions after two months (T0 242 μ, T1 285 μ, T3 253μ - p<0.02 ; T0-T3 p>0.02). The group taking only supplements showed the highest rate of decline after 1 week but at the end of two months returned to starting levels (T0 242μ, T1 290μ, T3 247μ - p<0.02; T0-T3 p>0.02). The group taking both drugs presented an average thickness which was inferior to those of the other groups after one week but then returned to starting conditions after 2 months(T0 246μ, T1 283μ, T3 255μ -p> 0.02; T0-T3 p>0.02).

Conclusions : The use of Resveratrol or of Resveratrol + NSAIDs can therefore control the post-surgery inflammatory process, positively influencing the evolution, in a pejorative sense, of an existing oedema.

This is an abstract that was submitted for the 2016 ARVO Annual Meeting, held in Seattle, Wash., May 1-5, 2016.


This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.